TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meets Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM IV) criteria for Bipolar I Disorder, Most Recent Episode Manic or Mixed (with or without psychotic features)~* history of at least 1 previously documented manic or mixed episode requiring medical treatment within 3 years before the screening phase~* total score of at least 20 on the YMRS at screening and at baseline~* if taking mood stabilizers, antipsychotics, or antimanic drugs, must have discontinued that medication at least 3 days before baseline~* women must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or agree to practice an effective method of birth control if they are sexually active before entry and throughout the study (effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier method, and male partner sterilization)~* able and willing to comply with self-administration of medication, or have consistent help or support available.~Exclusion Criteria:~* Meets DSM-IV criteria for rapid cycling and schizoaffective disorder~* In the opinion of the study doctor, is at significant risk for suicidal or violent behavior during the course of the study~* Has used cocaine, phencyclidine, amphetamine, methylphenidate, pemoline, an opioid (excluding codeine), hallucinogen, or any other drug that may be associated with manic symptoms as evidenced by a positive urine drug screen~* Has received benzodiazepines at doses equal to 4 mg/day of lorazepam or higher for a period of 3 months or longer immediately before the screening phase.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 003 (Type: PLACEBO_COMPARATOR): Placebo Daily for 3 weeks
- 002 (Type: ACTIVE_COMPARATOR): Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
- 001 (Type: EXPERIMENTAL): Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The child had been enrolled in the initial phase of the trial of seasonal vaccination with the RTS,S/AS01 vaccine~* A parent or legally recognised guardian provides informed consent for the child's inclusion in the extension study~* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial~The child is under five years of age at the time of enrolment.~Exclusion Criteria:~* The child has had an allergic reaction to the study drugs or vaccines~* The child had febrile convulsions on more than one occasion following vaccination~* The child has developed a serious underlying illness such as severe malnutrition (weight for age or mid arm circumference Z scores \< 3 SD) which in view of the investigators might impair the response to vaccination~* The child has been enrolled in another malaria vaccine or other experimental malaria intervention study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- SMC with SP+AQ (Type: ACTIVE_COMPARATOR): Administration of tetanus/diphtheria toxoids vaccine followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
- RTS,S/AS01 (Type: ACTIVE_COMPARATOR): Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1 and 2.
- RTS,S/AS01 plus SMC with SP+AQ (Type: ACTIVE_COMPARATOR): Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male/female, 18-75 years old, inclusive~* diagnosis of adult-onset RA~* had active disease~* had received methotrexate~* on a stable dose of folic acid~Exclusion Criteria:~* contraindication for methotrexate or anti-TNF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PREFER (Pacemaker Remote Follow-Up Evaluation and Review)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has been previously implanted with a dual-chamber or single-chamber EnPulse®, Kappa 900®, or Adapta® device~* Patient agrees to complete all required follow-up transmissions and in-office visits~* Patient is capable of operating the TTM monitor and Medtronic CareLink monitor~Exclusion Criteria:~* Patient is an immediate candidate for an implantable cardioverter defibrillator (ICD)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Transtelephonic monitoring at 2 month intervals
- Remote (Type: ACTIVE_COMPARATOR): Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Cough Reflex in Lung Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Lung transplant recipient~* Hemodynamically stable~* Capable of undergoing bronchoscopy~Exclusion Criteria:~* Pneumonia~* Hypoxemia (PaO2 \< 70)~* Hemodynamic instability~* Coagulopathy~* Thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stable lung transplant recipients (Type: None): All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a history of migraine with or without aura for more than one year, with between 2 and 8 moderate to severe attacks per month~* Patient is currently taking at least 50 mg topiramate daily for migraine prophylaxis~* Patient can distinguish between migraine and other types of headache~* Patient agrees to remain abstinent or use effective birth control during the study~Exclusion Criteria:~* Patient is pregnant or breast-feeding~* Patient has a history of mostly mild migraines or migraines that resolve within 2 hours~* Patient has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in the 3 months prior to screening.~* Patient was \> 50 years old at age of migraine onset~* Patient has history of heart disease~* Patient has uncontrolled hypertension~* Patient has had cancer within 5 years of screening (excepting certain skin and cervical cancers)~* Patient has started taking Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) or has changed doses within 3 months of screening~* Patient is taking more than one other migraine prophylactic medication~* Patient has repeatedly failed to respond to or tolerate rizatriptan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Treatment Sequence A: rizatriptan, rizatriptan, placebo
- B (Type: EXPERIMENTAL): Sequence B: rizatriptan, placebo, rizatriptan
- C (Type: EXPERIMENTAL): Sequence C: placebo, rizatriptan, rizatriptan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with type 2 diabetes mellitus managed by SU will be candidate for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function.~Exclusion criteria:~* Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm 1 (Type: EXPERIMENTAL): study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-term Efficacy of Treatment With Lamazym

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject must have participated in the phase 1 trial (EudraCT number: 2010-022084-36), phase 2a trial (EudraCT number: 2010-022085-26), phase 2b trial (EudraCT number: 2011-004355-40) or phase 3 trial (EudraCT number: 2012-000979-17)~2. The subject must still be receiving weekly intravenous infusions of Lamazym according to the AfterCare Program~3. The Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities~4. The subject and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~1. History of bone marrow transplantation~2. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial. Subjects unable to perform the motor tests independently from support are permitted to participate in the trial and will be evaluated for the remnant non motor endpoints~3. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial~4. Pregnant and/or lactating women cannot participate in the trial. Concerning women of child bearing potential (WOCBP), the investigators will decide whether or not there is a need for contraception. This assessment will be done through interviews with the patient and parents.~5. Participation in other interventional trials testing IMP, including rhLAMAN-07 (EudraCT number: 2013-000336-97) and rhLAMAN-09 (EudraCT number: 2013-000321-31) trials with Lamazym~6. Pause of the IMP for 2 consecutive weeks during the last month. Subjects are allowed to be re-screened

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamazym (Type: EXPERIMENTAL): 1 mg Lamazym/kg Body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Clinical Trial of Teriparatide in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients diagnosed with osteoporosis~* Aged 55 or older~* Patients who are at high risk for fracture~Exclusion Criteria:~* History of metabolic bone disorders other than primary osteoporosis~* History of malignant neoplasm in the 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated.~* Severe or chronically disabling conditions other than osteoporosis

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): 20 micrograms for 104 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years of age or older.~2. Patients must have a confirmed and documented RRMS diagnosis~3. Patients must be ambulatory with a Kurtzke EDSS score of 0 to 5.5 at screening visit.~4. Patients must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment 30 days prior to randomization.~5. Women of child-bearing potential must have a negative urine pregnancy test at screening visit and must practice an acceptable method of birth~6. Patients must be able to sign and date a written informed consent prior to entering the study.~7. Patients must be willing and able to comply with the protocol requirements for the duration of the study.~Exclusion Criteria~1. Patient had any contraindication to Copaxone therapy.~2. Previous use of Copaxone 40 mg/mL three times per week.~3. Patients with progressive forms of MS.~4. Patients with neuromyelitis optica.~5. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.~6. Patients who have been treated with; immunosuppressive medications, immunoglobulins and/or monoclonal antibodies, alemtuzumab, cladribine, cyclophosphamide or mitoxantrone at any time~7. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.~8. Pregnancy or breastfeeding.~9. Clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation~10. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals~    * other criteria may apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copaxone® 40 mg/mL (Type: EXPERIMENTAL): Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
- Copaxone® 20 mg/mL (Type: ACTIVE_COMPARATOR): Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma~* Largest tumor lesion ≤ 5 cm~* Palpable or nonpalpable breast lesion~  * Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions~* Prior (preoperative) or planned (intraoperative) sentinel node biopsy required~  * At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension~* No clinical evidence of distant metastases~  * No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:~    * Skeletal pain of unknown cause~   * Elevated alkaline phosphatase~   * Bone scan showing hot spots~* No palpable axillary lymph node(s)~* No Paget's disease without invasive cancer~* Hormone receptor status:~  * Estrogen receptor and progesterone receptor known~PATIENT CHARACTERISTICS:~Age~* Any age~Sex~* Female~Menopausal status~* Any status~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* See Disease Characteristics~Renal~* Not specified~Other~* Not pregnant or nursing~* No other prior or concurrent malignancy except the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Adequately treated carcinoma in situ of the cervix~ * Adequately treated in situ melanoma~ * Contralateral or ipsilateral carcinoma in situ of the breast~* No psychiatric, addictive, or other disorder that may compromise ability to give informed consent~* Geographically accessible for follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~Other~* No prior systemic therapy for breast cancer~* More than 1 year since prior chemopreventive agent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Axillary Dissection (Type: ACTIVE_COMPARATOR): Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
- No Axillary Dissection (Type: EXPERIMENTAL): Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9 kg/m2 and at least one obesity-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea)~* Ability to complete a 2 year study~Exclusion Criteria:~* Diabetes~* Pregnancy~* History of heart valve disease~* Serious or unstable current or past medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lorcaserin 10 mg BID (Type: EXPERIMENTAL): Lorcaserin 10 mg tablet each morning and evening
- Matching Placebo BID (Type: PLACEBO_COMPARATOR): Matching placebo tablet each morning and evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete